Panacea Innovation Ltd Decreases Stake in Atara Biotherapeutics to 16.1%

On May 11, 2026, Panacea Innovation Limited and associated entities filed Amendment No. 3 to their Schedule 13D regarding Atara Biotherapeutics, Inc. (ATRA). The filing reports a reduction in holdings following a transaction on May 7, 2026, where Panacea Venture Healthcare Fund II, L.P. sold 313,446 shares of Common Stock in open market transactions. These shares were sold at a weighted average price of $10.0975 per share. Following this sale, the reporting group, which includes James Huang, Panacea Venture Healthcare Fund II, and Panacea Opportunity Fund I, collectively beneficially owns 1,318,894 shares. This represents approximately 16.1% of the company's outstanding common stock, based on 8,178,114 shares outstanding as of March 2026. Panacea Venture Healthcare Fund II remains the record holder of 1,011,000 shares, while Panacea Opportunity Fund I holds 307,894 shares. James Huang, as the sole owner of Panacea Innovation Limited, maintains shared dispositive and voting power over the aggregate position.